John A. Hey

NormOxys, Inc. develops small-molecule therapeutics for the treatment of cancer. Its major product is OXY111A. The company was founded by Conrad J Bletzer, Jr. Claude Nicoalu, Jean-Mearie Lehn, Gay Goodman, Ruth Greferath and Roscoe Brady in 2004 and is headquartered in Brighton, MA.

Alzheon, Inc. engages in the provision of medical development. It specializes in treatment for brain health, memory, and aging. It offers ALZ-801, an oral small molecule inhibitor of amyloid formation and neurotoxicity with potential to be a therapy for a genetically defined population of patients with or at high risk for Alzheimer's disease and other neurodegenerative disorders. The company was founded by Martin Tolar in June 2013 and is headquartered in Framingham, MA.

CoMentis, Inc. focuses on developing drugs to treat various central nervous system disorders. Its research and development spectrum include BACE inhibitors and modulators of the a7 nicotinic acetylcholine receptor (NAChR). The company was founded by John P. Cooke and Muralitharan Kengatharan in 2006 and is headquartered in South San Francisco, CA.

Schering-Plough Research Institute provides pharmaceutical research. The company is headquartered in Kenilworth, NJ.